PeptideGlobal

Wegovy MASH guidance from Korean liver doctors arrives before local approval

The Korean Association for the Study of the Liver has set out who should get semaglutide for MASH, limiting it to F2 and F3 fibrosis without cirrhosis, while the liver indication still waits for a Korean regulatory decision.

Illustration for the story: Wegovy MASH guidance from Korean liver doctors arrives before local approval

Illustration by Peptide Global, not a picture of the place in the story.

The short of itKorea's liver society issued a consensus on using semaglutide for MASH in adults with F2 or F3 fibrosis and no cirrhosis, before the indication is approved in Korea.

Korea's liver specialists have written their rules for Wegovy MASH treatment before the drug is cleared for that use at home. The Korean Association for the Study of the Liver released a consensus statement on 20 November at KDDW 2026, the joint congress of Korean digestive disease societies. It names who should get semaglutide for metabolic dysfunction associated steatohepatitis, how to pick them with noninvasive tests and when to judge the result. The indication still waits for a Korean regulatory decision, and no date has been published.

What the Korean liver consensus recommends

The statement narrows treatment to adults with MASH and moderate to advanced scarring of the liver, fibrosis stages F2 and F3, who do not yet have cirrhosis. According to Korea Biomedical Review, the association advises against starting semaglutide only to improve liver inflammation or scarring in people with F1 fibrosis or none. Doctors are asked to find candidates in two steps. First comes the fibrosis 4 index, a score built from age and routine blood results. Patients flagged by that score then have vibration controlled transient elastography, a scan that estimates liver stiffness. The aim is to treat people at real risk of progression without sending every patient with fatty liver for a biopsy, which remains the reference test in trials.

On treatment itself, the consensus follows the regimen tested in the pivotal study. Patients start low and step up in four week intervals until they reach the weekly maintenance amount used in the trial, and the society asks doctors to favour that full regimen in people who also have type 2 diabetes and F2 or F3 disease. Response should be checked with noninvasive tests no earlier than 18 months after the first injection, a long horizon that reflects how slowly liver fibrosis changes. For readers outside Korea, the Wegovy MASH guidance matters because it is one of the first Asian society documents written for this use. It sets a selection model that insurers and hospitals in Korea can later copy into their own criteria.

ESSENCE trial numbers behind the advice

The recommendations rest on ESSENCE, the Phase 3 trial run by Novo Nordisk in adults with biopsy proven MASH and F2 or F3 fibrosis. Results from its first part, published in the New England Journal of Medicine in April 2025, were read at week 72. Fibrosis improved without any worsening of steatohepatitis in 36.8 percent of patients on semaglutide and 22.4 percent of those on placebo. Steatohepatitis resolved without worse fibrosis in 62.9 percent against 34.3 percent. Both endpoints come from liver biopsies, the measures that regulators accept for early approval in this disease. They are not outcomes such as cirrhosis, cancer or death, which the trial's second part is meant to measure over a longer period.

Fibrosis improved without any worsening of steatohepatitis in 36.8 percent of patients on semaglutide and 22.4 percent of those on placebo.

Put as simple differences, semaglutide beat placebo by about 14 percentage points on scarring and by about 29 points on inflammation. The gap is real but modest on fibrosis, the measure most closely tied to later liver failure, and that helps explain the careful patient selection in the Korean text. Placebo patients also improved in sizeable numbers, which is why the comparison between the two groups matters more than either raw rate. The Korean authors did not claim that the drug prevents cirrhosis or cancer, and they kept the response check far enough from the start of treatment for change to show. The table sets out what the consensus and the trial say, using only the figures the society cited.

ItemDetail
IssuerKorean Association for the Study of the Liver
Released20 November 2026 at KDDW 2026
Eligible patientsMASH with fibrosis F2 to F3 and no cirrhosis
SelectionFIB 4 index first, then transient elastography
Not advisedTreatment only for liver gain in F1 or lower
Response checkNoninvasive tests at least 18 months in
Trial basisESSENCE Phase 3, week 72 biopsy results
Fibrosis improved36.8 percent semaglutide, 22.4 percent placebo
Steatohepatitis resolved62.9 percent semaglutide, 34.3 percent placebo
Korean statusMASH indication awaiting regulatory approval

Safety rules and the Korean context

The statement spells out where caution is needed. Patients who develop pain under the right ribs during treatment should be checked for gallbladder disease, including gallstones and inflammation of the gallbladder. If acute pancreatitis is diagnosed, semaglutide should be stopped for good. People with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2 should not use it. These warnings match what doctors already know from the drug's use in obesity and diabetes, but the society chose to restate them for hepatologists, many of whom have less experience with GLP 1 drugs than endocrinologists. The liver group also said its advice reflects how Korean care is delivered and the social setting of the country.

That setting includes a worry the association named directly: misuse and overuse of the medicine. Korea has seen fast uptake of obesity drugs, and Peptide Global reported this week how three medical societies asked for obesity drug imports to be tracked from customs to clinic. Against that backdrop, a liver society that limits treatment to proven scarring is also drawing a line against use for mild fatty liver alone. Korean companies are working on rival liver drugs as well. Hanmi's licensed candidate efinopegdutide recently lifted broker valuations, as covered in Hanmi MASH valuations, which shows how crowded the local liver pipeline may become once semaglutide is approved.

Wegovy MASH approval and open questions

The next step belongs to the Korean regulator. The consensus does not say when a decision on the liver indication is due, and the company has not published a Korean timetable in the material reviewed for this story. In Europe, the regulator's file for the drug has been moving too; our report on the Wegovy EPAR update showed a pending label change on liver impairment but no new indication. Once a Korean approval arrives, the practical question shifts to coverage. Hospitals will need to decide whether to fund elastography for screening, and insurers will weigh the cost of long treatment against benefits that ESSENCE has so far shown only on biopsy.

The association also listed what it does not yet know. It wants longer follow up to learn whether treatment lowers rates of cirrhosis, liver cancer, transplant and liver deaths, and whether MASH returns when treatment stops. It asked for studies on the best amount and length of treatment, on combinations with other MASH drugs, and on efficacy and safety in Asian patients, Korean patients included. That last request is pointed, since body size and fat distribution often differ from the Western groups that dominate trial enrolment. Until such data exist, Korean doctors following the statement will rely on biopsy results gathered mostly elsewhere, read through local tests.

Conclusion

The Korean liver society has set out who should receive Wegovy MASH treatment once it is approved: adults with F2 or F3 fibrosis and no cirrhosis, picked with a blood score and a stiffness scan and checked after 18 months. The advice rests on ESSENCE biopsy results, not on hard outcomes. The approval date, insurance cover and data in Korean patients are still open.

Why it matters in South Korea

Korea has fast uptake of GLP-1 drugs and worries about misuse. A society rule that limits liver use to proven scarring, picked with a blood score and a stiffness scan, gives hospitals and insurers a model before approval arrives.

What to watch

The Korean regulatory decision on the MASH indication, insurance criteria that may copy the consensus, and the outcome data from the second part of ESSENCE.

Sources

  1. Korea Biomedical Review: Korean liver society issues Wegovy treatment recommendations for MASH ahead of approval
  2. Sanyal AJ et al. Phase 3 trial of semaglutide in metabolic dysfunction associated steatohepatitis. N Engl J Med 2025

Spotted a wrong figure? Tell the desk; we fix errors under our corrections policy.

Peptide Global reports news about medicines and markets. Nothing here is medical or investment advice.